Beta Bionics CCO sells 35,994 shares in plan trade

Amended Form 4 corrects Beta Bionics CCO Mark Hopman’s September 9, 2026 Rule 10b5-1 sale to 35,994 shares at $18.4628, leaving 88,033 shares owned.

This filing corrects an earlier one, and you can read the original Form 4 if you want to see what changed.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reports that Chief Commercial Officer Mark Hopman sold 35,994 shares of common stock on September 9, 2026 at $18.4628 per share in a sale described as open market or private. The sale was made pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

After this transaction, Hopman beneficially owned 88,033 shares of Beta Bionics common stock. This Form 4 amendment corrects an earlier filing that had incorrectly reported the number of shares disposed and the resulting beneficial ownership.

Insider Trade Summary 10b5-1

Net Seller: 35,994 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 35,994 shs ($665K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	35,994	$18.4628	$665K

Holdings After Transaction: Common Stock — 88,033 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026 (the "10b5-1 Plan").
2. F2. On September 10, 2026, the reporting person filed a Form 4 which incorrectly reported the number of shares disposed. The reporting person sold 35,994 shares under the 10b5-1 Plan on September 9, 2026 and the number of securities beneficially owned following the sale was 88,033 shares.

Key Figures

Shares sold: 35,994 shares Sale price per share: $18.4628 per share Shares beneficially owned after transaction: 88,033 shares +1 more

4 metrics

Shares sold 35,994 shares Common stock sold by Chief Commercial Officer on September 9, 2026

Sale price per share $18.4628 per share Price for the September 9, 2026 sale of 35,994 common shares

Shares beneficially owned after transaction 88,033 shares Beneficial ownership of Mark Hopman following the September 9, 2026 sale

Rule 10b5-1 Plan adoption date June 10, 2026 Date the trading plan covering the reported sale was adopted

Key Terms

Rule 10b5-1 Plan, beneficially owned, open market or private transaction

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

beneficially owned regulatory

"the number of securities beneficially owned following the sale was 88,033 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) disclose in this amended Form 4?

Beta Bionics disclosed that Chief Commercial Officer Mark Hopman sold 35,994 shares of common stock on September 9, 2026 at $18.4628 per share, in a sale described as taking place in the open market or in a private transaction.

Why did Beta Bionics (BBNX) file an amended Form 4 for Mark Hopman?

An amended Form 4 was filed because a prior Form 4 on September 10, 2026 incorrectly reported the number of shares disposed. The amendment states that 35,994 shares were sold and that 88,033 shares were beneficially owned after the sale.

How many Beta Bionics (BBNX) shares does Mark Hopman own after the reported sale?

After the September 9, 2026 sale, Mark Hopman beneficially owned 88,033 shares of Beta Bionics common stock, according to the amended disclosure that corrects the previously misreported post-transaction share count.

Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the 35,994 shares were sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, indicating the trades were executed under a pre-arranged trading plan.

At what price did Mark Hopman sell his Beta Bionics (BBNX) shares?

The amended filing reports that Mark Hopman sold 35,994 shares of Beta Bionics common stock at a price of $18.4628 per share on September 9, 2026 in a sale described as open market or private.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 07:52 PM Accepted by SEC EDGAR 09/18/2026 - 07:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/10/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		S(1)		35,994(2)	D	$18.4628	88,033(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026 (the "10b5-1 Plan").

2. On September 10, 2026, the reporting person filed a Form 4 which incorrectly reported the number of shares disposed. The reporting person sold 35,994 shares under the 10b5-1 Plan on September 9, 2026 and the number of securities beneficially owned following the sale was 88,033 shares.

	/s/ Stephen Feider, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)